Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’
15 January 2026
1 min read

Broadcom stock falls again as China targets VMware; RBC says OpenAI upside ‘less clear’

NEW YORK, Jan 15, 2026, 05:43 EST — Premarket

Broadcom Inc (AVGO) shares fell roughly 4.2% to $339.89 in premarket trading Thursday, following reports that China has instructed local companies to halt use of certain foreign cybersecurity software, including VMware, which Broadcom owns. (Jerusalem Post)

This report hits Broadcom’s software business, not just its chip division. It comes quickly too, as U.S.-China tech tensions stretch beyond export controls into the core infrastructure of corporate networks.

Traders are digesting new sell-side reports alongside a debt refinancing move Broadcom revealed in an SEC filing. Not exactly the recipe for a steady open.

Chinese authorities have ordered companies to halt use of cybersecurity software from over a dozen U.S. and Israeli firms, citing national security risks, according to three sources who spoke to Reuters. The U.S. companies named include Broadcom-owned VMware, Palo Alto Networks, and Fortinet. Reuters was unable to determine how many firms received the directive. Orca Security CEO Gil Geron, whose company was also reportedly targeted, called the ban “a step in the wrong direction.” (Reuters)

Broadcom dropped 4.15% during Wednesday’s regular session, underperforming as the tech selloff dragged the Nasdaq down and hit several chip stocks. Nvidia slipped 1.44%, according to MarketWatch data. (MarketWatch)

Uncertainty around China returned to the headlines this week. On Thursday, Reuters reported that China is working on new rules to limit how many advanced AI chips, including Nvidia’s H200, domestic companies can bring in. The story cites a report from Nikkei Asia. (Reuters)

Broadcom disclosed in an SEC filing that it has struck an underwriting deal to issue $4.5 billion in senior notes—unsecured corporate bonds—spanning four maturities. Coupon rates range from 4.300% due 2031 up to 5.700% due 2056. The company plans to deploy the net proceeds for general corporate needs and to pay down debt. It has also initiated redemption notices for several outstanding note series, including those linked to VMware. (SEC)

RBC Capital’s Srini Pajjuri kicked off coverage of Broadcom with a Sector Perform rating and set a $370 price target, highlighting ongoing concerns about margins and the staying power of big AI-related contracts. He noted that TPUs — tensor processing units, specialized AI chips for data centers — show near-term strength, but called the Anthropic ramp a “question mark” and described the OpenAI opportunity as “less clear.” (TipRanks)

The downside is straightforward: a broad, lasting China directive could push VMware’s customers toward local options, hurting renewals and stalling new business. But if the notice ends up narrow, patchily enforced, or gets rolled back, attention will shift back to AI demand and refinancing details.

Investors are gearing up for any updates from Broadcom, Chinese regulators, or other firms mentioned in the report. All eyes will be on whether the software blacklist expands beyond cybersecurity. The bond market is focused on upcoming redemption dates: Jan. 17, Jan. 22, and Feb. 6. (Investing)

Stock Market Today

  • BridgeBio Pharma Valuation After Attruby Uptake, BBP-418 Data, and Late-Stage Pipeline Momentum
    January 15, 2026, 6:33 AM EST. BridgeBio Pharma (BBIO) has drawn fresh attention after reporting more than 6,600 prescriptions for its ATTR-CM therapy Attruby, releasing interim Phase 3 data for BBP-418, and outlining a new TTR amyloid depleter program. Our latest analysis notes a 90-day share-price gain of 41.6% and a 3-year total shareholder return, with the stock near US$77.90. The fair value estimate stands around US$84.65, implying upside if late-stage programs convert to revenue and earnings. Analysts' consensus price target is US$63.81, with a range from US$41.00 to US$95.00. Risks include durability of Attruby, negative trial data, and regulatory delays. Valuation shows BridgeBio trading at a discount to our fair value, but a high P/S ratio (~42.4x vs 26.8x fair). A premium valuation hinges on execution and margin expansion.
Lottery.com stock steadies premarket after 80% surge, volatility pause puts SEGG in focus
Previous Story

Lottery.com stock steadies premarket after 80% surge, volatility pause puts SEGG in focus

Oakville teens land early funding for shark-deterring net as Halton board steps up mental health push
Next Story

Oakville teens land early funding for shark-deterring net as Halton board steps up mental health push

Go toTop